A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1557-1559

  Kopycinski, Jakub ^a   Cheeseman, Hannah ^a   Ashraf, Ambreen ^a   Gill, Dilbinder ^a   Hayes, Peter ^a   Hannaman, Drew ^b   Gilmour, Jill ^a   Cox, Josephine H ^a   Vasanc, Sandhya ^c,d,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Ichor Medical Systems Inc   (United States)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADVAX; ALPHA4 BETA7 INTEGRIN; BINDING PROTEIN; CD4 ANTIBODY; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL ACTIVITY; CELL DESTRUCTION; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; ELECTROPORATION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; NORMAL HUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; ELECTROPORATION; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMAN EXPERIMENTATION; HUMANS; INULIN; VACCINATION; VACCINES, DNA;

EID: 84865981605     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00327-12     Document Type: Article

References (28)

1. Arthos J, et al. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9:301-309. (Pubitemid 351267327)
2. Cicala C, et al. 2009. The integrin {alpha}4{beta}7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106:20877-20882.
3. de Souza MS, et al. 2012. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188:5166-5176.
4. Dolter KE, et al. 2011. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 29:795-803.
5. Fischer W, et al. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106. (Pubitemid 46067393)
6. Gill DK, et al. 2010. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 5:e14330. doi:10.1371/journal.pone. 0014330.
7. Goonetilleke N, et al. 2006. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80:4717-4728.
8. Harari A, et al. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205:63-77. (Pubitemid 351185716)
9. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
10. Huang Y, et al. 2008. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B′ recombinant. J. Acquir. Immune Defic. Syndr. 47:403- 411.
11. Koup RA, et al. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5:e9015. doi:10.1371/journal.pone. 0009015.
12. Letourneau S, et al. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984. doi:10.1371/journal.pone.0000984.
13. Li F, et al. 2011. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PLoS One 6:e20479. doi:10.1371/journal.pone.0020479.
14. Lim SG, et al. 1993. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin. Exp. Immunol. 92:448-454. (Pubitemid 23183754)
15. Liu Y, et al. 2006. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J. Virol. 80:9519-9529. (Pubitemid 44435628)
16. O'Rourke SM, et al. 2010. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 84:11200-11209.
17. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
18. Roederer M, Koup RA. 2003. Optimized determination of T cell epitope responses. J. Immunol. Methods 274:221-228. (Pubitemid 36263057)
19. Sanders RW, et al. 2008. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 5:10. doi:10.1186/1742-4690-5-10.
20. Sardesai NY, Weiner DB. 2011. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23:421-429.
21. Troyer RM, et al. 2009. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 5:e1000365. doi:10.1371/journal.ppat.1000365.
22. Vasan S, et al. 2011. Electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252. doi:10.1371/journal.pone.0019252.
23. Wagner R, et al. 1999. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 162:3727-3734. (Pubitemid 29313630)
24. Wang S, et al. 2008. Cross-subtype antibody and cellular immune responses induced by a polyvalentDNAprime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:1098-1110.
25. Winstone N, et al. 2011. Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J. Virol. 85:9578-9587.
26. Yang OO. 2009. Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation. PLoS One 4:e7388. doi:10.1371/ journal.pone. 0007388.
27. Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. 2011. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res. Hum. Retroviruses 27:391-398.
28. Zolla-Pazner S, Cardozo T. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10:527-535.